# BAT8008

Source: https://onco.cc/drugs/bat8008/  
OnCo record `bat8008` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BAT8008 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.

## Summary

ASCO 2025 abstract 3024 reports 170 enrolled patients at the January 15, 2025 cutoff, including 147 at the selected 2.4 mg/kg dose. Among efficacy-evaluable patients at that dose, cervical cancer ORR was 36.4% (22 patients) and esophageal cancer ORR 23.1% (13 patients). Two of six patients at 2.7 mg/kg had dose-limiting toxicity. Stomatitis and cytopenias included grade 3 or higher events. These selected nonrandomized cohorts do not establish breast-cancer efficacy.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: ADC
- Mechanism: TROP2-directed monoclonal antibody-drug conjugate delivering exatecan.
- Payload: Exatecan (TOP1 inhibitor)

## Sources

- Publisher abstract: https://doi.org/10.1200/jco.2025.43.16_suppl.3024
- ClinicalTrials.gov NCT05620017: https://clinicaltrials.gov/study/NCT05620017

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection](https://onco.cc/trials/nct05620017/)

---
JSON: https://onco.cc/api/v1/entities/bat8008.json